Compass Therapeutics' Combo Therapy Shows Around 38% Overall Response Rate In Pretreated Biliary Tract Cancer Patients

Compass Therapeutics Inc CMPX announced the presentation of data from a Phase 2 study of CTX-009 in combination with paclitaxel in patients with biliary tract cancers (BTC).
CTX-009, in combination with paclitaxel, demonstrated a 37.5% overall response rate (ORR) in 24 patients with BTC treated in the second-and third-line settings.
At least one response was observed in each of the four anatomical subtypes of BTC.
Seven of the 11 patients who had received one prior systemic therapy achieved a Partial Response, leading to an ORR of 63.6% in this sub-group.
After a median follow-up of approximately 12 months, the median progression-free survival was 9.4 months, and the median overall survival was 12.5 months.
Compass has initiated a randomized Phase 2/3 study of CTX-009 in combination with paclitaxel in the U.S. in patients with advanced BTC.
The study will enroll up to 150 patients with BTC who have received no more than one prior systemic therapy.
The study could support a biologics license application (BLA) submission as soon as H2 2024. The primary endpoint of the study is ORR.
Price Action: CMPX shares closed 10.93% lower at $3.75 on Thursday.